Decline in haemoglobin A1c values in diabetic patients receiving interferon-alpha and ribavirin for chronic hepatitis C

Journal of Viral Hepatitis

Volumn 13, Issue 9, 2006, Pages 613-617

  Greenberg, P D ^a   Rosman, A S ^a   Eldeiry, L S ^a   Naqvi, Z ^a   Brau N ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Diabetes mellitus; Haemoglobin A1c; Hepatitis C; Interferon alpha; Ribavirin; Therapy

Indexed keywords

ALPHA INTERFERON; GLUCOSE; HEMOGLOBIN A1C; LACTOSE DEHYDROGENASE; OXIDOREDUCTASE; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DIABETES MELLITUS; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HUMAN CELL; MALE; MEAN CORPUSCULAR VOLUME; NONHUMAN; PRIORITY JOURNAL; RETICULOCYTE COUNT; RETROSPECTIVE STUDY;

ANTIVIRAL AGENTS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES COMPLICATIONS; DIABETES MELLITUS; ERYTHROCYTE INDICES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HEMOGLOBINS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; RETICULOCYTE COUNT; RETROSPECTIVE STUDIES; RIBAVIRIN;

EID: 33747195548     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00729.x     Document Type: Article

References (18)

1. Bunn HF, Haney DN, Kamin S, Gabbay KH, Gallop PM. The biosynthesis of human hemoglobin A1c. Slow glycosylation of hemoglobin in vivo. J Clin Invest 1976; 57 (6): 1652-1659.
2. Dusheiko G, Main J, Thomas H et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25 (5): 591-598.
3. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks vs interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus; International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352 (9138): 1426-1432.
4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27 (Suppl. 1): S5-S10.
5. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22 (6): 696-699.
6. Panzer S, Kronik G, Lechner K, Bettelheim P, Neumann E, Dudczak R. Glycosylated hemoglobins (GHb): an index of red cell survival. Blood 1982; 59:1348-1350.
7. Wiener K. A falling HbA1c is not necessarily an indicator of improving diabetes control. Ann Clin Biochem 2001; 38 (Pt 4): 406-407.
8. Atabani GS, Hassan DA, Abdul Rahman AM, Saeed BO. Glycosylated hemoglobin levels in Sudanese sickle cell anemia patients. Acta Haematol 1989; 81 (3): 140-142.
9. Eberentz-Lhomme C, Ducrocq R, Intrator S, Elion J, Nunez E, Assan R. Haemoglobinopathies, malaria, and other interferences with HBA1 assessment. Diabetes Metab 1984; 10 (5): 304-310.
10. Ho CH, Chau WK, Yu TJ, Cheng KK. Diagnostic value of glycosylated hemoglobin in intravascular hemolysis after cardiac surgery. Eur J Haematol 1990; 45 (3): 139-142.
11. Polgreen PM, Putz D, Stapleton JT. Inaccurate glycosylated hemoglobin A1C measurements in human immunodeficiency virus-positive patients with diabetes mellitus. Clin Infect Dis 2003; 37 (4): e53-e56.
12. De Franceschi L, Fattovich G, Turrini F et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31 (4): 997-1004.
13. Tanaka H, Shiota G, Kawasaki H. Changes in glucose tolerance after interferon-alpha therapy in patients with chronic hepatitis C. J Med 1997; 28 (5-6): 335-346.
14. Konrad T, Vicini P, Zeuzem S et al. Interferon-alpha improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease. Exp Clin Endocrinol Diabetes 1999; 107 (6): 343-349.
15. Tai TY, Lu JY, Chen CL et al. Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C. J Endocrinol 2003; 178 (3): 457-465.
16. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25 (2): 275-278.
17. Lindsey CC, Carter AW, Mangum S et al. A prospective, randomized, multicentered controlled trial to compare the annual glycemic and quality outcomes of patients with diabetes mellitus monitored with weekly fructosamine testing vs usual care. Diabetes Technol Ther 2004; 6 (3): 370-377.
18. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133 (8): 592-599.